What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2?

Marc Hellerstein

doi:10.1016/j.jvacx.2020.100076

Related publications

Article2020

Repurposing CD8 <sup>+</sup> T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?

Shashi Gujar, Jonathan Pol, Youra Kim, Guido Guido Kroemer

Article2022

Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted Agents

Flora Zagouri, Alkistis Papatheodoridi, Michalis Liontos, Αlexandros Briasoulis, Aimilia D. Sklirou, Efthymia Skafida, Oraianthi Fiste, Christos Markellos, Αngeliki Andrikopoulou, Konstantinos Koutsoukos, Maria Kaparelou, Eirini Gkogkou, Ioannis P. Trougakos, Meletios A Dimopoulos, Evangelos Terpos

Letter2023

Defective Immunity Against SARS-CoV-2 Omicron Variants Despite Full Vaccination in Hematologic Malignancies

Laurence Zitvogel, Lisa Derosa, Guido Guido Kroemer

Article2021

Seroprevalence of antibodies to SARS-CoV-2 in healthcare workers: a cross-sectional study

Joseph E. Ebinger, Gregory J. Botwin, Christine M. Albert, Mona Alotaibi, Moshe Arditi, Anders H. Berg, Aleksandra Binek, Patrick Botting, Justyna Fert‐Bober, Jane C. Figueiredo, Jonathan Grein, Wohaib Hasan, Mir Henglin, Shehnaz K. Hussain, Mohit Jain, Sandy Joung, Michael Karin, Elizabeth H. Kim, Dalin Li, Yunxian Liu, Eric Luong, Dermot McGovern, Akil Merchant, Noah Merin,

Article2022

Third Dose of the BNT162b2 Vaccine Results in Sustained High Levels of Neutralizing Antibodies Against SARS-CoV-2 at 6 Months Following Vaccination in Healthy Individuals

Ioannis Ntanasis‐Stathopoulos, Vangelis Karalis, Aimilia D. Sklirou, Maria Gavriatopoulou, Harry Alexopoulos, Panagiotis Malandrakis, Ioannis P. Trougakos, Meletios A Dimopoulos, Evangelos Terpos